HUP9802078A2 - LCK SH2 specifikus vegyületek felhasználása autoimmun betegségek és szövetátültetési kilökődési reakció kezelésére - Google Patents

LCK SH2 specifikus vegyületek felhasználása autoimmun betegségek és szövetátültetési kilökődési reakció kezelésére

Info

Publication number
HUP9802078A2
HUP9802078A2 HU9802078A HUP9802078A HUP9802078A2 HU P9802078 A2 HUP9802078 A2 HU P9802078A2 HU 9802078 A HU9802078 A HU 9802078A HU P9802078 A HUP9802078 A HU P9802078A HU P9802078 A2 HUP9802078 A2 HU P9802078A2
Authority
HU
Hungary
Prior art keywords
domain
lck
binds
binding affinity
autoimmune diseases
Prior art date
Application number
HU9802078A
Other languages
English (en)
Inventor
Damien John Dunnington
Original Assignee
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corporation filed Critical Smithkline Beecham Corporation
Publication of HUP9802078A2 publication Critical patent/HUP9802078A2/hu
Publication of HUP9802078A3 publication Critical patent/HUP9802078A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A találmány aűtőimműn betegségek kezelésére, szövetátültetésikilökődési reakció gátlására és/vagy imműnszűpresszió kiváltásáraszőlgáló eljárásőkra vőnatkőzik. A találmány szerinti eljárásők sőrána kezelés alanyának gyógyászatilag hatásős, illetve a szövetátültetésikilökődési reakciót gátló és/vagy imműnszűppressziót indűkálómennyiségben beadnak egy őlyan vegyületet, amely (a) egy hűmán lck SH2dőménhez ötvenszeresnél nagyőbb kötési affinitással kötődik, mintamekkőra kötési affinitással a vegyület egy hűmán sc SH2 dőménhez ésegy hűmán fyn SH2 dőménhez kapcsőlódik, és (b) egy hűmán SHPTP2 SH2dőménhez és egy hűmán p85 SH2 dőménhez ötvenszeresnél nagyőbb kötésiaffinitással kötődik, mint amekkőra kötési affinitással a vegyület azilyen lck SH2 dőménhez kapcsőlódik. ŕ
HU9802078A 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection HUP9802078A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38638195A 1995-02-10 1995-02-10
US40022095A 1995-03-07 1995-03-07
US49735795A 1995-06-30 1995-06-30

Publications (2)

Publication Number Publication Date
HUP9802078A2 true HUP9802078A2 (hu) 1998-12-28
HUP9802078A3 HUP9802078A3 (en) 1999-04-28

Family

ID=27409758

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802078A HUP9802078A3 (en) 1995-02-10 1996-02-09 Use of lck sh2 specific compounds to treat autoimmune diseases and allograft rejection

Country Status (10)

Country Link
EP (2) EP0809490A4 (hu)
JP (2) JPH10513474A (hu)
KR (1) KR19980702115A (hu)
AU (1) AU4923796A (hu)
BR (1) BR9607614A (hu)
CA (1) CA2212645A1 (hu)
FI (1) FI973259A (hu)
HU (1) HUP9802078A3 (hu)
NO (1) NO973659L (hu)
WO (1) WO1996024343A1 (hu)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5922697A (en) * 1996-10-02 1999-07-13 Warner-Lambert Company Compounds, compositions and methods for inhibiting the binding of proteins containing an SH2 domain to cognate phosphorylated proteins
JP4485520B2 (ja) 2003-03-24 2010-06-23 エフ．ホフマン−ラ ロシュ アーゲー 逆転写酵素阻害剤としてのベンジル−ピリダジノン類
EP1730120A1 (en) 2004-03-23 2006-12-13 F.Hoffmann-La Roche Ag Non-nucleoside reverse transcriptase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5136093A (en) * 1992-09-25 1994-04-26 Warner-Lambert Company Peptide antagonists of sh2 binding and therapeutic uses thereof
US5580979A (en) * 1994-03-15 1996-12-03 Trustees Of Tufts University Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions
US5710129A (en) * 1995-02-23 1998-01-20 Ariad Pharmaceuticals, Inc. Inhibitors of SH2-mediated processes

Also Published As

Publication number Publication date
AU4923796A (en) 1996-08-27
EP0811159A1 (en) 1997-12-10
FI973259A0 (fi) 1997-08-07
NO973659D0 (no) 1997-08-08
JPH10513474A (ja) 1998-12-22
NO973659L (no) 1997-10-08
EP0809490A1 (en) 1997-12-03
EP0809490A4 (en) 1999-10-20
CA2212645A1 (en) 1996-08-15
HUP9802078A3 (en) 1999-04-28
JPH10513564A (ja) 1998-12-22
FI973259A (fi) 1997-10-08
BR9607614A (pt) 1998-06-09
KR19980702115A (ko) 1998-07-15
WO1996024343A1 (en) 1996-08-15

Similar Documents

Publication Publication Date Title
BG101966A (en) Application of 1l-agonist for the treatment of lack of urine retention
NO974680D0 (no) Anvendelse av midler som frigir nitrogenholdig oksyd for behandling av impotens
BR9711805A (pt) Compostos e métodos para providenciar preparações farmacologicamente ativas e uso dos mesmos
NL300224I1 (nl) 3-Benzazepinzonen gesubstitueerd met een benzocyclobutyl-of indanylalkyla-minoalkylgroep, bruikbaar voor de behandeling van cardiovasculaire aandoeningen.
FI962557A0 (fi) PLA2-inhibiittoreiden käyttö Alzheimerin taudin hoidossa
TR199902071T2 (xx) Heterosiklik bile�ikler ve bunlar�n �-amilioid peptidinin inhibisyonunda kullan�m�
DE69728594D1 (de) Chromfreie Zusammensetzung zur Behandlung von Metalloberflächen
PT705100E (pt) Guanidinas substituidas terapeuticas
NO307687B1 (no) Anvendelse av riluzol ved fremstilling av medikamenter for behandling av neuro-AIDS
DE69612465T2 (de) Verwendung von Rifamyciderivaten zur Behandlung von Chlamydia-Infektionen
FR2777781B1 (fr) Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
FR2670669B1 (fr) Instrument de correction chirurgicale de l'astigmatisme.
DE69426767D1 (de) Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
DE69405919T2 (de) Zusammensetzungen zur Behandlung von Keratinfasern
GB2380939B (en) Treatment or prevention of auto-immune diseases
HUP9600455A3 (en) Use of quinoxalines combined with protease-inhibiting compounds for producing pharmaceutical compositions for treating aids and/or hiv infections
KR960030947A (ko) src SH2 특이성 화합물의 골흡수 질환 치료 용도
HUP9802078A2 (hu) LCK SH2 specifikus vegyületek felhasználása autoimmun betegségek és szövetátültetési kilökődési reakció kezelésére
FR2710267B3 (fr) Composition pour le traitement de l'impuissance masculine.
NO912091D0 (no) Fremgangsmaate for inhibering av avleiringer og avleiringsinhiberende sammensetning.
ZA969490B (en) Compounds useful for the inhibition of the replication of hiv-1 and hiv-1 mutants
NO993627L (no) Anvendelse av en forbindelse for fremstilling av et legemiddel
NO982562D0 (no) Sammensetning for behandling av smerte
HUP9802842A2 (hu) Fungicid keverékek
EP1039931A4 (en) MULTIVALENT RECOMBINANT ANTIBODIES FOR THE TREATMENT OF HUMAN RHINOVIRUS (HRV) INFECTIONS